Pharmacokinetics: Drug Biotransformation

Pharmacokinetics: drug biotransformation is the critical process by which the body converts lipophilic drugs into hydrophilic metabolites for elimination. This comprehensive JoVE Coach course covers Phase I functionalization and Phase II conjugation reactions, examining how enzymes transform medications like aspirin, codeine, and acetaminophen in liver cells to prevent toxic accumulation while maintaining therapeutic effects.

• Understand the fundamental principles of drug biotransformation and its role in pharmacokinetics
• Learn the mechanisms of Phase I oxidative, reductive, and hydrolytic reactions
• Identify specific enzyme systems that metabolize common medications like phenytoin and diazepam
• Explore Phase II conjugation pathways including glucuronidation and sulfation
• Analyze how drug structure influences metabolic pathways and enzyme interactions
• Apply knowledge of biotransformation factors to predict drug behavior in patients
• Understand genetic polymorphisms affecting drug metabolism like acetylation variations
• Examine how disease states and environmental factors alter drug biotransformation rates

1. Phase I Biotransformation Mechanisms: Phase I reactions represent catabolic processes that introduce or expose polar functional groups in drug molecules. These functionalization reactions include oxidative processes catalyzed by cytochrome P450 enzymes, reductive reactions that add electrons to carbonyl groups, and hydrolytic reactions that cleave ester and amide bonds. For example, aspirin undergoes hydrolysis to form salicylic acid, while codeine experiences O-dealkylation to produce morphine. These reactions typically occur in liver microsomes and serve as the first step in preparing lipophilic drugs for elimination or further conjugation.

2. Phase II Conjugation Reactions: Phase II biotransformation involves anabolic conjugation reactions where polar endogenous molecules attach to drugs or Phase I metabolites. Major pathways include glucuronidation using UDP-glucuronic acid, sulfation with 3'-phosphoadenosine-5'-phosphosulfate (PAPS), and glutathione conjugation for detoxification. Acetaminophen exemplifies multiple conjugation pathways, forming both glucuronide and sulfate conjugates for elimination. These reactions are capacity-limited and can become saturated at high drug doses, potentially leading to toxicity when alternative metabolic pathways predominate.

3. Enzyme Systems and Drug Metabolism: Drug-metabolizing enzymes exhibit significant diversity in their substrate specificity and catalytic mechanisms. Cytochrome P450 mixed-function oxidases require molecular oxygen and NADPH to catalyze oxidative reactions, while transferases like UDP-glucuronosyltransferases facilitate conjugation reactions. Enzyme induction by drugs like phenobarbital can accelerate metabolism, while inhibition by compounds like cimetidine can slow drug clearance. Understanding these enzyme systems helps predict drug-drug interactions and individual variations in drug response, particularly important for medications with narrow therapeutic windows.

4. Factors Affecting Drug Biotransformation: Multiple biological and chemical factors influence drug metabolism rates and pathways. Physicochemical properties including molecular size, lipophilicity, and pKa determine enzyme-substrate interactions. Biological factors encompass genetic polymorphisms (such as acetylation phenotypes), age-related changes in enzyme activity, sex differences in metabolism, and disease states affecting liver function. Environmental factors like smoking and dietary components can induce or inhibit metabolizing enzymes. These variations explain why the same drug dose may produce different effects in different patients, necessitating personalized dosing strategies.